IRON Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -4.59%, SMA50 -10.87%, SMA200 -1.0%). The stock’s 14-day RSI is 45.34 (neutral), while the ATR of 5.32 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -31.75% below its high and over 120.34% above its low. Average 10-day trading volume of 668.43 thousand shares is below the 3-month average of 744.17 thousand, indicating normal recent market interest.

Disc Medicine, Inc. has 34.77 million shares outstanding. The public float is 28.68 million shares, elevated short interest at 7.24% of float. This equals 2.26 million shares. The short ratio is 6.54 days. Institutional investors hold 113.83% of the float. Insiders own 10.61%. AI DMI LLC holds 2.81 million shares, Quisel John D has 226.06 thousand shares and Atlas Venture Fund X, L.P. has 198.33 thousand shares. Over the past six months, insider transactions show net selling. They sold 857.96 thousand shares across 24 transactions.

Disc Medicine, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.53. This means the shares are trading above this model’s fair value.

Disc Medicine, Inc. (NASDAQ:IRON) closed at $64.87 USD, gaining $0.64 (1.00%) from the previous close of $64.23. The stock is currently mid-range between its 52-week high and low $30.82 and $99.50. With a market capitalization of about $2.48 billion, Disc Medicine, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~2.66). Key stats such as the average daily volume over the past year has been around 756.02 thousand shares, volume is running light vs its 52-week average. Headquartered in Watertown, MA, Disc Medicine, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO John D. Quisel, the company employs approximately 94 people and listed since August 12, 2020. Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases.

Disc Medicine, Inc. generated EPS of -$5.36 over the past year. Five-year average earnings growth is 38.12%. Wall Street analysts project EPS growth of -21.26% annually over the next five years. The latest quarter delivered EPS of -$1.77. The next quarter is forecast at -$1.71. Next year's EPS is expected at -$28.82. Analyst sentiment is bullish. Analyst rating data shows there are 13 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $153.00 to $79.00. The high target offers 138.21% upside. The low target suggests 23.0% downside. The mean target is $113.65. This offers 76.94% upside. Disc Medicine, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 19.59%. The prior quarter beat by 35.04%. Over the last six quarters, Apple has recorded several small beats. These include -7.21% in August 08, 2024.

Disc Medicine, Inc. trades at a P/E ratio of -10.6, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.04 trading at moderately above to book value. The P/FCF stands at -13.42, also below market averages.

Our AI price prediction model suggests that Disc Medicine, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -8.98%, with price expected at $58.46 by March 23, 2026, within a range of $53.18 to $63.76 3-Month Outlook: Projected fall of -18.08%, reaching $52.62 by June 05, 2026, with a range of $50.96 to $54.31. 1-Year Outlook: Projected gain of 14.18%, with price at $73.34 by March 09, 2027, within a range of $68.94 to $78.05.

Disc Medicine, Inc. (NASDAQ:IRON) shares are flat -6.81% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Disc Medicine, Inc. trading at a premium to the broader market with a P/E of -10.6. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $84.00, suggesting 30.78% upside. Our AI forecast model points to short-term weakness (-8.98% over two weeks), a medium-term fall (-18.08% over three months), and a longer-term gain (14.18% over one year), with expected trading ranges indicating moderate volatility.